Skip to main content
Top
Published in: Pediatric Cardiology 1/2014

01-01-2014 | Original Article

Assessment of Early-Onset Chronic Progressive Anthracycline Cardiotoxicity in Children: Different Response Patterns of Right and Left Ventricles

Authors: Abdullah Kocabaş, Fırat Kardelen, Halil Ertuğ, Bilge Aldemir-Kocabaş, Özgür Tosun, Akif Yeşilipek, Volkan Hazar, Gayaz Akçurin

Published in: Pediatric Cardiology | Issue 1/2014

Login to get access

Abstract

We aimed to assess early-onset chronic progressive cardiotoxicity in the left and right ventricles with increasing cumulative anthracycline doses. We evaluated 72 patients within the first year after doxorubicin and/or daunorubicin treatment (median 1.3 months; range 0.3–11.5) and 31 healthy controls. Pretreatment and posttreatment QT interval analyzes were performed in 27 newly diagnosed patients. The echocardiographic data of all examinations of 72 patients were classified into three groups according to instant cumulative anthracycline doses: treatment group (TG)-I (≤120 mg/m2; n = 26), TG-II (120–240 mg/m2; n = 39), and TG-III (≥240 mg/m2; n = 40). Diastolic and systolic parameters were analyzed by conventional echocardiography and tissue Doppler imaging (TDI) and compared with those of healthy controls. The mean age for patients and controls was 8.2 ± 4.5 and 9.6 ± 4.2 years, respectively (p > 0.05). QTc dispersion significantly increased after anthracycline treatment (p = 0.02). TDI showed decreased E′ velocity (p < 0.001) and E′/A′ ratio (p < 0.001) at lateral tricuspid annulus segment in TG-I, and these findings continued in TG-II and -III. In addition, S′ velocity decreased in TG-I, -II, and -III at lateral mitral annulus (10.5 ± 2.6 cm/s, p < 0.05; 9.9 ± 2.2 cm/s, p < 0.001; and 10.1 ± 2.3 cm/s, p < 0.01, respectively). However, decrease in left-ventricular ejection fraction was statistically significant in TG-II and -III (p < 0.001). Although myocardial performance index was significantly increased in all treatment groups in both segments, it was primarily due to significant increases in isovolumic relaxation time at the lateral tricuspid annulus and isovolumic contraction time at the lateral mitral annulus. Abnormalities in diastolic function in right ventricle and systolic function in the left ventricle were observed even with a cumulative anthracycline dose <120 mg/m2 by TDI. In addition, anthracycline treatment led to an increase in QTc dispersion.
Literature
1.
go back to reference Ayhan SS, Özdemir K, Kayrak M, Bacaksiz A et al (2012) The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler-derived myocardial performance index. Cardiol J 19:363–368CrossRefPubMed Ayhan SS, Özdemir K, Kayrak M, Bacaksiz A et al (2012) The evaluation of doxorubicin-induced cardiotoxicity: comparison of Doppler and tissue Doppler-derived myocardial performance index. Cardiol J 19:363–368CrossRefPubMed
2.
go back to reference Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Exp Opin Pharmacother 8:1039–1058CrossRef Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE (2007) Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Exp Opin Pharmacother 8:1039–1058CrossRef
3.
go back to reference Baysal T, Koksal Y, Oran B, Sen M et al (2010) Cardiac functions evaluated with tissue Doppler imaging in childhood cancers treated with anthracyclines. Pediatr Hematol Oncol 27:13–23CrossRefPubMed Baysal T, Koksal Y, Oran B, Sen M et al (2010) Cardiac functions evaluated with tissue Doppler imaging in childhood cancers treated with anthracyclines. Pediatr Hematol Oncol 27:13–23CrossRefPubMed
4.
go back to reference Chanan-Khan A, Srinivasan S, Czuczman M (2004) Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2:251–266PubMed Chanan-Khan A, Srinivasan S, Czuczman M (2004) Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2:251–266PubMed
5.
go back to reference Di Lisi D, Bonura F, Macaione F, Peritore A et al (2011) Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. Anticancer Drugs 22:468–472CrossRefPubMed Di Lisi D, Bonura F, Macaione F, Peritore A et al (2011) Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. Anticancer Drugs 22:468–472CrossRefPubMed
6.
go back to reference Dodos F, Halbsguth T, Erdmann E, Hoppe UC (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97:318–326CrossRefPubMed Dodos F, Halbsguth T, Erdmann E, Hoppe UC (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97:318–326CrossRefPubMed
7.
go back to reference Dorup I, Levitt G, Sullivan I, Sorensen K (2004) Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart 90:1214–1216PubMedCentralCrossRefPubMed Dorup I, Levitt G, Sullivan I, Sorensen K (2004) Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart 90:1214–1216PubMedCentralCrossRefPubMed
8.
go back to reference Eidem BW, Sapp BG, Suarez CR, Cetta F (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120–1122CrossRefPubMed Eidem BW, Sapp BG, Suarez CR, Cetta F (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120–1122CrossRefPubMed
9.
go back to reference Galetta F, Franzoni F, Cervetti G, Cecconi N et al (2005) Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59:541–544CrossRefPubMed Galetta F, Franzoni F, Cervetti G, Cecconi N et al (2005) Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59:541–544CrossRefPubMed
10.
go back to reference Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4:235–242CrossRefPubMed Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4:235–242CrossRefPubMed
11.
12.
go back to reference Hudson MM, Rai SN, Nunez C, Merchant TE et al (2007) Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 25:3635–3643CrossRefPubMed Hudson MM, Rai SN, Nunez C, Merchant TE et al (2007) Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 25:3635–3643CrossRefPubMed
13.
go back to reference Isaaz K, Thompson A, Ethevenot G, Cloez JL et al (1989) Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol 64:66–75CrossRefPubMed Isaaz K, Thompson A, Ethevenot G, Cloez JL et al (1989) Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol 64:66–75CrossRefPubMed
14.
go back to reference Kapusta L, Groot-Loonen J, Thijssen JM, DeGraaf R, Daniëls O (2003) Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol 41:426–435CrossRefPubMed Kapusta L, Groot-Loonen J, Thijssen JM, DeGraaf R, Daniëls O (2003) Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol 41:426–435CrossRefPubMed
15.
go back to reference Karakurt C, Koçak G, Ozgen U (2008) Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 25:880–887CrossRefPubMed Karakurt C, Koçak G, Ozgen U (2008) Evaluation of the left ventricular function with tissue tracking and tissue Doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 25:880–887CrossRefPubMed
16.
go back to reference Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819–829CrossRefPubMed Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13:819–829CrossRefPubMed
17.
go back to reference Kulakowski P, Karczmarewicz S, Czepiel A, Makowska E et al (2001) QT interval dispersion in ventricular beats: a noninvasive marker of susceptibility to sustained ventricular arrhythmias. Pacing Clin Electrophysiol 24:352–357CrossRefPubMed Kulakowski P, Karczmarewicz S, Czepiel A, Makowska E et al (2001) QT interval dispersion in ventricular beats: a noninvasive marker of susceptibility to sustained ventricular arrhythmias. Pacing Clin Electrophysiol 24:352–357CrossRefPubMed
18.
go back to reference Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR et al (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815CrossRefPubMed Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR et al (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815CrossRefPubMed
19.
go back to reference Lipshultz S, Alvarez J, Scully R (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525–533CrossRefPubMed Lipshultz S, Alvarez J, Scully R (2008) Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94:525–533CrossRefPubMed
20.
go back to reference Macfarlane PW, McLaughlin SC, Devine B, Yang TF (1994) Effects of age, sex, and race on ECG interval measurements. J Electrocardiol 27:14–19CrossRefPubMed Macfarlane PW, McLaughlin SC, Devine B, Yang TF (1994) Effects of age, sex, and race on ECG interval measurements. J Electrocardiol 27:14–19CrossRefPubMed
21.
go back to reference Mertens A, Yasui Y, Neglia J, Potter J et al (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163–3172PubMed Mertens A, Yasui Y, Neglia J, Potter J et al (2001) Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 19:3163–3172PubMed
22.
go back to reference Nakamae H, Hino M, Akahori M, Terada Y et al (2004) Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol 76:1–7CrossRefPubMed Nakamae H, Hino M, Akahori M, Terada Y et al (2004) Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation. Am J Hematol 76:1–7CrossRefPubMed
23.
go back to reference Ocal B, Oguz D, Karademir S, Birgen D et al (2002) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 23:522–527CrossRefPubMed Ocal B, Oguz D, Karademir S, Birgen D et al (2002) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo/Doppler indices. Pediatr Cardiol 23:522–527CrossRefPubMed
24.
go back to reference Oeffinger K, Mertens A, Sklar C, Kawashima T et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582CrossRefPubMed Oeffinger K, Mertens A, Sklar C, Kawashima T et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582CrossRefPubMed
25.
go back to reference Orditura M, Sarubbi B, Devita F, Ducceschi V et al (1997) Prolonged corrected QT dispersion. Oncol Rep 4:1047–1050PubMed Orditura M, Sarubbi B, Devita F, Ducceschi V et al (1997) Prolonged corrected QT dispersion. Oncol Rep 4:1047–1050PubMed
26.
go back to reference Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefPubMed Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539–2550CrossRefPubMed
27.
go back to reference Ruggiero A, De Rosa G, Rizzo D, Leo A et al (2012) Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol. doi:10.1007/s10147-012-0458-9 Ruggiero A, De Rosa G, Rizzo D, Leo A et al (2012) Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol. doi:10.​1007/​s10147-012-0458-9
28.
go back to reference Sarubbi B, Orditura M, Ducceschi V, De Vita F et al (1997) Ventricular repolarization time indexes following anthracycline treatment. Heart Vessels 12:262–266CrossRefPubMed Sarubbi B, Orditura M, Ducceschi V, De Vita F et al (1997) Ventricular repolarization time indexes following anthracycline treatment. Heart Vessels 12:262–266CrossRefPubMed
29.
go back to reference Senju N, Ikeda S, Koga S, Miyahara Y et al (2007) The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart Vessels 22:393–397CrossRefPubMed Senju N, Ikeda S, Koga S, Miyahara Y et al (2007) The echocardiographic Tei-index reflects early myocardial damage induced by anthracyclines in patients with hematological malignancies. Heart Vessels 22:393–397CrossRefPubMed
30.
go back to reference Shankar SM, Marina N, Hudson MM, Hodgson DC et al (2008) Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 121:e387–e396CrossRefPubMed Shankar SM, Marina N, Hudson MM, Hodgson DC et al (2008) Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 121:e387–e396CrossRefPubMed
31.
go back to reference Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97:1991–1998CrossRefPubMed Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID (2003) Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 97:1991–1998CrossRefPubMed
32.
go back to reference Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677CrossRefPubMed Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672–1677CrossRefPubMed
33.
go back to reference Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM et al (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children’s Cancer Study Group. Pediatrics 89:942–949PubMed Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM et al (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children’s Cancer Study Group. Pediatrics 89:942–949PubMed
34.
go back to reference Trachtenberg BH, Landy DC, Franco VI, Henkel JM et al (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342–353CrossRefPubMed Trachtenberg BH, Landy DC, Franco VI, Henkel JM et al (2011) Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol 32:342–353CrossRefPubMed
35.
go back to reference van Dalen EC, van den Brug M, Caron HN, Kremer LC (2006) Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 42:3199–3205CrossRefPubMed van Dalen EC, van den Brug M, Caron HN, Kremer LC (2006) Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 42:3199–3205CrossRefPubMed
36.
go back to reference Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B (2012) Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Survivor 6:95–101CrossRef Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B (2012) Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Survivor 6:95–101CrossRef
37.
go back to reference Von Hoff DD, Layard MW, Basa P, Davis HL Jr et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717CrossRef Von Hoff DD, Layard MW, Basa P, Davis HL Jr et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717CrossRef
38.
go back to reference Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ (1991) Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 337:816–818CrossRefPubMed Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ (1991) Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 337:816–818CrossRefPubMed
Metadata
Title
Assessment of Early-Onset Chronic Progressive Anthracycline Cardiotoxicity in Children: Different Response Patterns of Right and Left Ventricles
Authors
Abdullah Kocabaş
Fırat Kardelen
Halil Ertuğ
Bilge Aldemir-Kocabaş
Özgür Tosun
Akif Yeşilipek
Volkan Hazar
Gayaz Akçurin
Publication date
01-01-2014
Publisher
Springer US
Published in
Pediatric Cardiology / Issue 1/2014
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-013-0745-x

Other articles of this Issue 1/2014

Pediatric Cardiology 1/2014 Go to the issue